Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

BIOALLIANCE PHARMA SA (C4X)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (EUR)
Sales 2018 2,20 M
EBIT 2018 -17,1 M
Net income 2018 -14,1 M
Finance 2018 7,48 M
Yield 2018 -
Sales 2019 3,45 M
EBIT 2019 -10,1 M
Net income 2019 -10,6 M
Debt 2019 1,84 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 24,4x
EV / Sales2019 18,3x
Capitalization 61,2 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
06/19ONXEO : Press Release
CO
06/12ONXEO : S.A. Secures a $7.5 Million Royalty and Milestone Monetization Financing..
AQ
06/07ONXEO : Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporati..
PU
05/16ONXEO : Annual General Meeting of May 16, 2018
PU
05/16ONXEO : Proxy Statments
CO
05/16ONXEO : 1st quarter earnings
CO
05/01ONXEO SA : quaterly earnings release
04/27ONXEO : Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA for Treat..
AQ
04/25ONXEO : Combined General Meeting on May 16, 2018
PU
04/25ONXEO : Publication of 2017 Registration Document
PU
More news
Sector news : Pharmaceuticals - NEC
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 2
Average target price 1,55 €
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA71
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785
MERCK AND COMPANY9.24%165 373